The first and only FDA approved

at-home tDCS treatment for depression.

Flow FL-100 is intended for the treatment of moderate to severe major
depressive disorder (MDD) in the current episode, either as monotherapy or as
an adjunctive treatment, in patients 18 years and older who are not considered
treatment refractory to medication.

Start prescribing

Advancing Psychiatry

In 2026

Flow FL-100 introduces a first-line neuromodulation treatment to your early-intervention strategy. Requiring no prior medication failure, Flow FL-100 seamlessly expands your treatment options, whether you are:

Managing a newly diagnosed patient,
Introducing augmentation for a partial response to a current antidepressant,
Optimizing a patient's existing treatment plan,
Expanding treatment options for specialized or underserved patient populations

Could Flow FL-100 be right for your patients?

In the pivotal 10-week, multisite, double-blind, randomized sham-controlled superiority trial published in Nature Medicine, more than half of the participants in the active group achieved full remission*†. Results demonstrate that Flow FL-100 is highly effective both as a standalone monotherapy and as an adjunct to antidepressant medication1.

57,5%

Flow FL-100 has been prescribed internationally since 2019. Throughout this wide-spread real-world use, the device has maintained an exceptional safety profile, with fewer than 5% of patients reporting mild, transient side effects2.

66,000

Bring Flow FL-100

to Your Practice

Beginning September 1st 2026, Flow FL-100 will be available for US prescription. To support your practice, we’ve created a simple journey to get started prescribing Flow:

1 – Register
Enter your NPI number and clinic details 
to register for online certification.
2 – Get certified‡
Complete our mandatory short provider certification program at your own pace (typically less than 1 hour).
3 – Prescribe
Select Flow FL-100 in your EHR formulary. Our nationwide partner pharmacy handles fulfillment and ships the device straight to your patient's door.
Footnote
*Remission is defined as a score of <10 on MADRS. MADRS remission rate was a secondary endpoint of the study. The primary endpoint of the study reviewed between-group mean difference in HDRS-17 scores and was –2.3 points in favour of the active group (p=0.
†Comparison of monotherapy and adjunctive use of Flow FL-100 was a sub-analysis evaluation included as table 10 and 11 in the Empower Study.
‡While the FDA does not require a risk evaluation strategy, our data from 60,000+ patients shows that brief provider onboarding drastically improves clinical outcomes.
References: 1. Woodham, R.D., Selvaraj, S., Lajmi, N. et al. Nat Med (2024). 2. Data on file. Flow Neuroscience Real-world reports. 2025.